Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Health Catalyst, Inc. (HCAT) SEC Filings & Earnings Calls

EquiReason read 27 Health Catalyst, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Appointment of Tami Reller to the Board of Directors, effective October 1, 2026, filling a newly created seat and serving as audit chair and compensation committee member. The appo.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HCATHealth Catalyst, Inc.Follow HCAT — free
Health Information Services · Healthcare
—
Price chart with a free account
Market cap
127.2M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
10 Nov, in 17 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

14 Sep 20268-K · 5.02, 7.01Appointment of Tami Reller to the Board of Directors, effective October 1, 2026, filling a newly created seat and serving as audit chair and compensation committee member. The appointment is part of a board expansion and follows the namingSEC ↗
8 Sep 20268-K · 5.02, 7.01Health Catalyst appoints Simeon Kohl as CEO and President; Ben Albert becomes Chief Business Officer.SEC ↗
8 Sep 2026SC 13D/APalogic Value Management disclosed a 7.1% activist stake in Health Catalyst and sent a letter requesting a clear business plan and enhanced disclosure.open

Figures in the filing · each found in the filing text

Beneficial ownership · 2026-09-045,374,949
Ownership percentage · 2026-09-047.1%

Risks flagged

Activist pressure may lead to strategic changes

“Palogic Value Management requested that the Board of Directors of the Issuer provide investors a clear, forward-looking business plan.”
Read the original on SEC EDGAR ↗
8 Sep 2026SC 13D/ASchedule 13D/A: Palogic Value Management, LP 7.1%SEC ↗
6 Aug 20268-K · 1.02, 2.01, 2.02, 7.01Health Catalyst exceeded high end of revenue guidance and midpoint of adjusted EBITDA guidance in Q2 2026; also repaid credit facility debt and completed Vitalware divestiture.open

Figures in the filing · each found in the filing text

Total revenue · Q2-2026$70M-13% y/y
Gross profit · Q2-2026$28M-8% y/y
Gross margin · Q2-202640.0%
Net loss · Q2-2026$-41M+1% y/y
Adjusted EBITDA · Q2-2026$10M+6% y/y
Adjusted Gross Profit · Q2-2026$36M-10% y/y
Adjusted Gross Margin · Q2-202651.0%

Guidance

Q3 2026 revenue $55-56M, Adjusted EBITDA $0-0.5M; FY2026 revenue $246-249M, Adjusted EBITDA $18-18.5M

Guidance provided for Q3 and FY2026; revenue and adjusted EBITDA ranges consistent with prior expectations.

Risks flagged

Revenue decline of 13% YoY; divestiture impact and potential ongoing headwinds.

“Total revenue $70,487 ... (13)%”
Read the original on SEC EDGAR ↗
6 Aug 202610-QHCAT reports ongoing demand weakness from DOS-to-Ignite migration, multiple restructuring plans, and goodwill impairments, with negative impact from Vitalware divestiture.earningsopen

Figures in the filing · each found in the filing text

Revenue from three largest clients (2025) · FY202513.6%
Revenue from three largest clients (2024) · FY202413.8%
Goodwill impairment charge (2025) · FY2025$105M
Goodwill impairment charge (2026) · FY2026$96M

Guidance

Future total revenue, gross profit, net income, Adjusted Gross Profit, and Adjusted EBITDA will be negatively impacted due to Vitalware divestiture

Management expects negative impact from Vitalware divestiture and ongoing churn from Ignite migration, with no specific guidance range provided.

Risks flagged

Client concentration risk

“Our three largest clients during 2025 comprised 5.7%, 4.4%, and 3.5% of our revenue, or 13.6% in the aggregate.” · word for word

Restructuring execution risk

“Project Nexus and any other or future restructuring or cost optimizing efforts may disrupt our operations and performance, and could lead to dissatisfaction or a reduction in morale among our workforce, attrition, or otherwise harm our relationship with our team members.” · word for word

Ignite migration churn risk

“We have also continued to experience churn or down-selling particularly related to the migration of our DOS platform clients to our Ignite platform, and may further experience churn or down-selling as a result of the Vitalware Transaction.” · word for word

Macroeconomic and funding cut risk

“These uncertainties in our end market could cause potential delays in client decisions.” · word for word
Read the original on SEC EDGAR ↗
22 Jun 2026SC 13DPalogic Value Management disclosed a 6.7% passive stake and expressed support for management's recent strategic moves.SEC ↗
22 Jun 2026SC 13DPalogic Value Management disclosed a 6.7% passive stake and expressed support for management's recent strategic moves.SEC ↗
8 Jun 2026SC 13D/AWhetstone Capital Advisors reports 4.5% passive/hedged stake in Health Catalyst via funds, with long options and short positions, no new activist intent.open

Risks flagged

Potential activist or hedging activity

“Item 4. Purpose of Transaction See the Schedule 13D.” · word for word
Read the original on SEC EDGAR ↗
8 Jun 2026SC 13D/AWhetstone Capital Advisors reports 4.5% passive/hedged stake in Health Catalyst via funds, with long options and short positions, no new activist intent.open

Risks flagged

Potential activist or hedging activity

“Item 4. Purpose of Transaction See the Schedule 13D.” · word for word
Read the original on SEC EDGAR ↗
4 Jun 20268-K · 1.01, 7.01Health Catalyst (HCAT) entered a Unit Purchase Agreement to sell its subsidiary Vitalware, LLC to Med-Metrix, LLC. The transaction involves the sale of equity interests and related assets.being acquiredSEC ↗
3 Jun 2026DEF 14AProxy statement filed for 2026 Annual Meeting; includes proposals to elect directors, ratify auditor, approve executive compensation, and declassify the board.open

Figures in the filing · each found in the filing text

Total Revenue · FY2025$311M+1% y/y
Technology Revenue · Technology · FY2025$208M+7% y/y
Professional Services Revenue · Professional Services · FY2025$103M-8% y/y
GAAP Net Loss · FY2025$178M+156% y/y
Adjusted EBITDA · FY2025$41M+59% y/y
Adjusted Net Income · FY2025$13M-23% y/y
Platform Clients · FY2025162+25% y/y
Net New Platform Clients · FY202532
Goodwill Impairment · FY2025$105M
Adjusted EBITDA Margin · FY202513.0%

Risks flagged

Goodwill Impairment Risk

“The increased net loss in 2025 compared to 2024 is largely driven by $105.4 million of goodwill impairment, which is primarily due to overall declines in our stock price and market capitalization.” · word for word

Revenue Growth Deceleration

“Total revenue was $311.1 million, an increase of 1% year-over-year.” · word for word

Professional Services Revenue Decline

“professional services revenue was $102.9 million, a decrease of 8% year-over-year.” · word for word

Stock Price Decline

“The increased net loss in 2025 compared to 2024 is largely driven by $105.4 million of goodwill impairment, which is primarily due to overall declines in our stock price and market capitalization.” · word for word
Read the original on SEC EDGAR ↗
11 May 20268-K · 2.02Health Catalyst Q1 2026 revenue $70.8M (-11% YoY), adjusted EBITDA $9.1M (+46% YoY), guides Q2 and FY26; strategic reset underway.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$71M-11% y/y
Adjusted EBITDA · Q1-2026$9M+46% y/y
Net Loss · Q1-2026$-111M+368% y/y
Gross Profit · Q1-2026$28M-3% y/y
Gross Margin · Q1-202639.0%
Adjusted Gross Profit · Q1-2026$36M-7% y/y
Adjusted Gross Margin · Q1-202651.0%

Guidance

Q2 2026 revenue $68M-$70M, adjusted EBITDA $9M-$10M; FY26 revenue $260M-$265M, adjusted EBITDA $30M-$33M

New guidance issued for Q2 and FY26; revenue decline expected to continue but adjusted EBITDA growth indicates margin focus.

Risks flagged

Revenue decline of 11% YoY; client churn and down-sell risk from DOS to Ignite migration.

“Total revenue down 11%; at-risk ARR may churn or down-sell in 2026 and 2027.”

Net loss widened to $(111.0)M from $(23.7)M; potential impairment or restructuring charges.

“Net loss $(111.0)M vs $(23.7)M, down 368%.”
Read the original on SEC EDGAR ↗
11 May 202610-QHealth Catalyst reported Q1 2026 revenue of $70.8M, down 11% YoY, with a net loss of $111M including a $95.5M goodwill impairment, but Adjusted EBITDA improved to $9.1M.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q1-2026$71M-11% y/y
Technology Revenue · Technology · Q1-2026$49M-4% y/y
Professional Services Revenue · Professional Services · Q1-2026$21M-24% y/y
Gross Margin · Q1-202639.0%
Adjusted EBITDA · Q1-2026$9M
Goodwill Impairment · Q1-2026$96M
Net Loss · Q1-2026$-111M

Guidance

Expects near-term revenue headwinds from Medicaid cuts and platform migration; expects Adjusted EBITDA to improve long-term but near-term growth slower.

Management expects near-term revenue pressure from Medicaid cuts and platform migration, but sees margin expansion from restructuring. No specific numeric guidance provided.

Risks flagged

Platform Migration Churn

“We have been notified of $12.5 million of ARR down-sell and churn and estimate we have $52.0 million of at risk ARR related to the DOS to Ignite migration.” · word for word

Medicaid Funding Cuts

“On July 4, 2025, President Trump signed the OBBBA into law, which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years and will create additional financial strain for many of our clients and prospective clients.” · word for word

Goodwill Impairment Risk

“Further declines in our stock price and market capitalization could result in further impairment charges, which could adversely affect our results of operations.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 202610-K/AThis 10-K/A amendment only contains Part III executive compensation and governance disclosures; no business, MD&A, risk factors, or guidance sections. Extracted signals are limited to compensation-related performance metrics and management changes.open

Risks flagged

Executive turnover risk

“Daniel Burton retired as Chief Executive Officer effective February 12, 2026; multiple board resignations.”

Goodwill impairment risk

“Impairment of goodwill and intangible assets was recognized... $110,223 thousand.”

Revenue growth shortfall

“Revenue Growth Rate Achievement... Actual Result 1.5% vs. Target 10.0%.”
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
27 Apr 20268-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open

Risks flagged

Workforce reduction may indicate underlying operational or financial challenges, though framed as strategic transformation.

“The Company expects this initiative to reduce its global workforce by approximately 9% and eliminate approximately 100 additional open, budgeted headcount positions... representing a meaningful reduction in the Company's cost structure.”
Read the original on SEC EDGAR ↗
13 Mar 2026SC 13D/AFirst Light Asset Management and Mathew P. Arens filed an amended Schedule 13D, maintaining a combined ~18.3% stake in Health Catalyst.SEC ↗
13 Mar 2026SC 13D/AFirst Light Asset Management and Mathew P. Arens filed an amended Schedule 13D, maintaining a combined ~18.3% stake in Health Catalyst.SEC ↗
12 Mar 20268-K · 2.02HCAT reports FY2025 total revenue $311.1M (+1% YoY), Adjusted EBITDA $41.4M (+59% YoY); Q1 2026 guidance: revenue $68-70M, Adj. EBITDA $7-8M; no FY2026 guidance due to CEO transition review.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · FY2025$311M+1% y/y
Adjusted EBITDA · FY2025$41M+59% y/y
Gross Margin · FY202538.7%
Adjusted Gross Margin · FY202551.1%
Net Loss · FY2025$-178M+156% y/y
Platform Clients · FY2025162+25% y/y
Dollar-based Retention Rate · FY202593.0%
Cash and Cash Equivalents · Q4-2025$51M-80% y/y
Short-term Investments · Q4-2025$45M-68% y/y

Guidance

Q1 2026 revenue $68-70M; Q1 2026 Adjusted EBITDA $7-8M

Q1 2026 guidance provided; no FY2026 guidance due to CEO transition; margin improvement expected.

Risks flagged

Significant cash burn: cash and investments declined from $392M to $95.7M; net loss widened to $178M.

“Cash and cash equivalents $50.8M (down from $249.6M); short-term investments $44.9M (down from $142.4M); net loss $(178.0)M”

Client retention declining: dollar-based retention rate dropped to 93% from 102%, indicating churn or downsell.

“Dollar-based Retention Rate 93% vs 102%”

CEO transition and lack of FY2026 guidance create strategic uncertainty.

“We are not providing forward-looking guidance for the full year of 2026 at this time due to an ongoing internal strategic and operational review in connection with our CEO transition.” · word for word
Read the original on SEC EDGAR ↗
12 Mar 202610-KAnnual 10-K filing with no explicit beat or miss; reports client metrics and retention rates.earningsopen

Figures in the filing · each found in the filing text

Platform Clients · FY2025162
App Clients · FY20251,000
Dollar-based Retention Rate · FY202593.0%
Documented Improvements · FY20252,000

Risks flagged

Competitive pressure from larger companies

“many of our competitors and potential competitors have significantly greater financial, technological, and other resources and name recognition than we do” · word for word

Regulatory compliance costs

“Our business is subject to extensive, complex, and rapidly changing federal and state laws and regulations” · word for word
Read the original on SEC EDGAR ↗
18 Feb 2026SC 13D/ASchedule 13D/A: Whetstone Capital Advisors, LLC 8.2%SEC ↗
21 Jan 2026SC 13DSchedule 13D: Whetstone Capital Advisors, LLC 7.4%SEC ↗
12 Jan 20268-K · 2.02Preliminary FY2025 revenue slightly above ~$310M guidance, Adj. EBITDA ~$41M in line, net new Platform Clients 32 vs target 30, Dollar-Based Retention Rate 93%. Guidance for 2026 bookings growth.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · FY2025$310M
Adjusted EBITDA · FY2025$41M
Net new Platform Clients · FY202532
Dollar-Based Retention Rate · FY202593.0%

Guidance

FY2025 revenue slightly above ~$310M; Adj. EBITDA ~$41M; FY2026 bookings expected to exceed 2025.

Preliminary FY2025 results slightly beat revenue guidance, Adj. EBITDA in line, client additions ahead of target. 2026 bookings expected to grow, with cost optimization via AI and India resourcing.

Risks flagged

Preliminary results subject to change upon completion of audit; potential adjustments.

“These preliminary unaudited estimated results are subject to change upon completion of the Company’s accounting and annual audit procedures and are therefore subject to adjustment.” · word for word

Ignite migration timeline adjusted; some clients prefer to remain on DOS, posing retention risk.

“We have adjusted our timeline and approach to be more client-centric, recognizing that some organizations prefer to remain on DOS for the near to medium term.” · word for word
Read the original on SEC EDGAR ↗
3 Dec 2025SC 13DSchedule 13D: First Light Asset Management, LLC 19.68%SEC ↗
10 Nov 20258-K · 2.02Health Catalyst reported Q3 2025 revenue of $76.3M and Adjusted EBITDA of $12.0M, beating guidance on both measures. Gross margin improved to 39% from 36% YoY. Full-year 2025 guidance reaffirmed.earningsopen

Figures in the filing · each found in the filing text

Total revenue · Q3-2025$76M-0% y/y
Gross profit · Q3-2025$30M+8% y/y
Gross margin · Q3-202539.0%
Net loss · Q3-2025$-22M-51% y/y
Adjusted Gross Profit · Q3-2025$40M+11% y/y
Adjusted Gross Margin · Q3-202553.0%
Adjusted EBITDA · Q3-2025$12M+64% y/y

Guidance

Q4 2025: total revenue ~$73.5M, Adjusted EBITDA ~$13.4M; FY2025: total revenue ~$310M, Adjusted EBITDA ~$41M

Guidance reaffirmed with Q4 and full-year targets consistent with prior outlook; management expresses confidence in sustained performance.

Risks flagged

Revenue flat YoY, indicating potential market saturation or competitive pressure.

“Total revenue $76,323K vs $76,353K, essentially flat”

Net loss widened to $22.2M from $14.7M, though partly due to non-cash items.

“Net loss $(22,229)K vs $(14,726)K, a 51% increase”
Read the original on SEC EDGAR ↗
10 Nov 202510-QNo material event; filing is a routine quarterly risk factor update with no specific earnings or guidance event.open

Risks flagged

Client concentration risk

“Our three largest clients during 2024 comprised 5.5%, 4.4%, and 3.9% of our revenue, or 13.8% in the aggregate.” · word for word

Platform migration execution risk

“the migration of existing clients using our DOS Solution to Health Catalyst Ignite involves risk and may cause disruptions to our Solution, difficulties as clients acclimate to a new platform, or other challenges that could impair our clients’ use of our technology, any of which could lead to client dissatisfaction, lower revenue, and non-renewals.” · word for word

Macroeconomic and funding cuts risk

“Recent macroeconomic challenges (including high inflationary and/or high interest rate environments, uncertainty with tariffs, cuts in Medicaid and research funding, or market volatility and measures taken in response thereto), and the tight labor market continue to adversely affect workforces, organizations, governments, clients, economies, and financial ma” · word for word
Read the original on SEC EDGAR ↗

Health Catalyst, Inc. — questions

What did Health Catalyst, Inc. file recently?
27 SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Appointment of Tami Reller to the Board of Directors, effective October 1, 2026, filling a newly created seat and serving as audit chair and compensation committee member. The appointment is part of a board expansion and follows the naming

Every figure on this page comes from Health Catalyst, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.